- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04230356
Trial of Scheduled Versus Treatment Administration of Donor-Derived Viral Specific T-cells for Viral Infections After Stem Cell Transplant
A Randomized Trial of Scheduled Versus Treatment Administration of Donor-Derived Viral Specific T-cells (VSTs) for Control of Viral Infections After Allogeneic Stem Cell Transplant
The purpose of this research study is to learn more about the use of viral specific T-lymphocytes (VSTs) to prevent or treat viral infections that may happen after allogeneic stem cell transplant. Allogeneic means the stem cells come from another person. VSTs are cells specially designed to fight viral infections that may happen after a stem cell transplant (SCT).
Stem cell transplant reduces the body's ability to fight infections. Viral infections are a common problem after transplant and can cause significant complications. Moreover, treatment of viral infections is expensive and time consuming, with families often administering prolonged treatments with intravenous anti-viral medications, or patients requiring prolonged admissions to the hospital. The medicines can also have side effects like damage to the kidneys or reduction in the blood counts, so in this study the investigators are trying to find a better way to treat these infections.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Celeste Dourson, MS
- Phone Number: 513-636-7679
- Email: Celeste.Dourson@cchmc.org
Study Contact Backup
- Name: Jamie Wilhelm, BS
- Phone Number: 513-803-1102
- Email: Jamie.Wilhelm@cchmc.org
Study Locations
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Recruiting
- Cincinnati Children's Hospital Medical Center
-
Contact:
- Celeste Dourson, MS
- Phone Number: 513-636-7679
- Email: Celeste.Dourson@cchmc.org
-
Principal Investigator:
- Stella Davies, MBBS, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
SCHEDULED ARM:
Inclusion Criteria:
- Recipient must be at least 21 days after stem cell infusion
- Clinical status must allow tapering of any steroids to < 0.5mg/kg prednisone or other steroid equivalent
- No critical illness making VST infusion hazardous
Exclusion Criteria:
- Active acute GVHD grades II-IV.
- Uncontrolled relapse of malignancy.
- Infusion of ATG or alemtuzumab within 2 weeks prior to VST infusion. Alemtuzumab levels will be collected in the second week following stem cell infusion in patients who received alemtuzumab as part of their conditioning regimen. The level must be less than or equal to 0.15 prior to infusion of VSTs. In patients with level greater than 0.15, alemtuzumab levels can be checked serially until a level ≤ 0.15 is obtained. They would become eligible for scheduled VST infusion at that point.
TREATMENT ARM
Inclusion Criteria:
- Blood adenovirus PCR ≥1,000
- Blood CMV PCR ≥ 500
- Blood EBV PCR ≥ 9,000
- Plasma BKV PCR >1,000
- Evidence of invasive adenovirus infection. Adenovirus infection will be defined as the presence of adenoviral positivity as detected by PCR or culture from one site such as stool or blood or urine or nasopharynx. Adenovirus disease will be defined as the presence of adenoviral positivity as detected by culture or PCR from more than 2 sites such as stool or blood or urine or nasopharynx.
- Evidence of invasive CMV infection, defined as pneumonitis, retinitis, colitis, hepatitis
- Evidence of EBV-associated lymphoproliferation (EBV-LPD) defined as proven EBV-LPD by biopsy or probable EBV-LPD defined as an elevated EBV DNA level in the blood associated with clinical symptoms (adenopathy or fever or masses on imaging) but without biopsy confirmation.
- Evidence of symptomatic BK virus infection, defined as hemorrhagic cystitis or BK nephropathy.
- No active acute GVHD grades II-IV
- No uncontrolled relapse of malignancy
- No infusion of ATG or alemtuzumab within 2 weeks of VST infusion.
- Clinical status must allow tapering of any steroids to < 0.5mg/kg prednisone or other steroid equivalent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: VSTs to Treat
VSTs will be given only if a viral infection develops.
|
VSTs will be infused into stem cell transplant recipients only if viremia is detected.
|
Experimental: VSTs to Prevent
VSTs are given through an IV infusion 21-30 days after transplant to see if the VSTs will help prevent a viral infection.
|
VSTs will be infused into stem cell transplant recipients on schedule.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Treatment Failures
Time Frame: 21 - 100 days after transplant
|
Treatment failure is defined as EBV>100,000, BKV >100,000, CMV >5,000 or Adv >50,000 at any time post randomization.
|
21 - 100 days after transplant
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Stella Davies, MBBS, PhD, Children's Hospital Medical Center, Cincinnati
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019-1217
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Viral Infection
-
Hospices Civils de LyonRecruiting
-
Materia Medica HoldingCompletedAcute Respiratory Viral InfectionRussian Federation
-
National Cancer Institute (NCI)CompletedViral InfectionsUnited States
-
University of Wisconsin, MadisonCompletedRespiratory Viral InfectionUnited States
-
Sinovac Biotech Co., LtdWithdrawnInfection, Viral, EnterovirusChina
-
Sinovac Biotech Co., LtdCompletedInfection, Viral, EnterovirusChina
-
National Institute of Allergy and Infectious Diseases...Completed
-
University of Missouri-ColumbiaTerminatedRespiratory Viral InfectionUnited States
-
Xlear, IncMetanoic Health Ltd.Not yet recruitingRespiratory Viral Infection
-
Catherine BollardActive, not recruiting
Clinical Trials on Viral Specific T-cells (VSTs) Scheduled
-
Children's Hospital Medical Center, CincinnatiHoxworth Blood CenterActive, not recruitingSolid Organ Transplant | Viral InfectionUnited States
-
Children's Hospital Medical Center, CincinnatiHoxworth Blood CenterWithdrawn
-
Children's Hospital Medical Center, CincinnatiHoxworth Blood CenterCompletedAllogeneic Stem Cell Transplant | Viral InfectionUnited States
-
Children's National Research InstituteActive, not recruitingViral Infections | Bone Marrow Transplant InfectionUnited States
-
Sun Yat-sen UniversityUnknownNasopharyngeal CarcinomaChina
-
AlloVirBaylor College of Medicine; The Methodist Hospital Research Institute; Center...Completed
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...Active, not recruitingLeukemia, Lymphoblastic (Acute)United States
-
Baylor College of MedicineCancer Prevention Research Institute of Texas; The Methodist Hospital Research... and other collaboratorsRecruitingAcute Myeloid Leukemia | Myelodysplastic SyndromeUnited States
-
New York Medical CollegeJohns Hopkins University; University of Colorado, Denver; Children's Hospital... and other collaboratorsRecruitingPrimary Immune Deficiency Disorder | AdenovirusUnited States
-
Memorial Sloan Kettering Cancer CenterWithdrawnEBV Lymphomas | EBV-associated Malignancies